Off-treatment antiviral efficacy and safety of repeat dosing of imdusiran followed by VTP-300 with or without nivolumab in virally-suppressed, non-cirrhotic subjects with chronic hepatitis B (CHB)

Conference Reports for NATAP

EASL - European Association
for the Study of the Liver
May 7-10, 2025
Amsterdam the Netherlands


Off-treatment antiviral efficacy and safety of repeat dosing of imdusiran followed by VTP-300 with or without nivolumab in virally-suppressed, non-cirrhotic subjects with chronic hepatitis B (CHB)

	EASL 2025 May 7-10 Amsterdam